New Delhi: Swiss biologics contract development and manufacturing organisation ExcellGene SA on Tuesday said it has partnered with Bharat Biotech and the University of Sydney to develop a.
CEPI will fund the initiative under its USD 200 million programme to advance the development of vaccines that provide broad protection against SARS-Cov-2 variants and other betacoronaviruses.
CEPI on Tuesday said it will provide up to USD 19.3 million (about Rs 149 crore) to Bharat Biotech International, the University of Sydney, and Switzerland-based ExcellGene SA for the development of a "variant-proof" SARS-CoV-2 vaccine candidate.
Get latest articles and stories on India at LatestLY. Bharat Biotech International Ltd (BBIL) on Tuesday said its COVID-19 vaccine, Covaxin, has received emergency use approval in children 6-12 years of age in India. India News | Bharat Biotech s Covaxin Gets Emergency Approval for 6-12 Age Group.
Three Cities and One Mission - Open The Magazine openthemagazine.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openthemagazine.com Daily Mail and Mail on Sunday newspapers.